PLAYSTUDIOS to Release Third Quarter 2023 Results November 2

GlobeNewswire
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health Analyses of patients with non-classical EGFR mutations reveal that the majority receive frontline chemotherapy and the remainder are treated with osimertinib or afatinib Short time to treatment discontinuation ranging from four to eight months demonstrates clear unmet need for patients with non-classical EGFR mutant NSCLC CAMBRIDGE, Mass., Sept. 14, 2024 (GLOBE NEWSWIRE) -- Black
Evening Standard
Pope Francis launches scathing attack on Donald Trump and Kamala Harris in shock US election intervention
The Pope blasted Harris's pro-abortion stance and Trump's immigration policies
BBC
Funeral begins for Ugandan Olympian killed by ex-boyfriend
The death, after being set ablaze, of marathon runner Rebecca Chepetegei shocked the world.
Yahoo News Australia
New dash cam trend on our roads that should spark fear in all of us
It's praiseworthy that drivers are using their new devices to dob on poor motoring, but will this be the beginning of a slippery slope? asks Adam Lucius.
The Independent
Biden scolds Sky News journalist for question on Putin’s Nato war threats
Joe Biden repeatedly told Sky News correspondent James Matthews to ‘be quiet’ during fiery exchange
The Independent
Strictly Come Dancing live: BBC show returns under a cloud of controversy as celebrity pairings to be revealed
The BBC favourite has been embroiled in scandal ahead of its big return to screens for its 20th anniversary
GlobeNewswire
RYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
Post-progression outcomes showed significant and sustained improvement for amivantamab plus chemotherapy versus chemotherapy alone1 BEERSE, BELGIUM , Sept. 14, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced updated results from the Phase 3 MARIPOSA-2 study which showed RYBREVANT®▼ (amivantamab) combined with chemotherapy led to consistent benefit across post-progression outcomes in adult patients with previously treated non-small cell lung c
Business Wire
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma
RAHWAY, N.J., September 14, 2024--KEYTRUDA plus trastuzumab and chemotherapy OS results as first-line treatment in patients with HER2-positive advanced gastric or GEJ adenocarcinoma.
Variety
International Oscar Race: Nepal Selects ‘Shambhala’
Nepal has selected “Shambhala” as its Oscar entry in the international feature film category. Directed by Min Bahadur Bham, “Shambhala” – a mystic, sacred realm in Tibetan Buddhism, also an area of significance in Hinduism, which means a place of peace – begins in a Himalayan polyandrous village in Nepal, where pregnant Pema faces scrutiny …
GlobeNewswire
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically significant segregation of responders in BM+ vs BM- subgroups based on OncoSignature patient selection (p-value = 0.009) ACR-368 endometrial cohort data maturing with all responders still on therapy; mDoR not yet reached (~6 months at time of data-cut) Endometrial cancer now anticipated to be the first tu
BBC
No new pledge on Ukraine missiles after Starmer-Biden talks
Ukraine has repeatedly urged the UK and US to let it fire long-range missiles against targets inside Russia.
Business Wire
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
NEW YORK, September 14, 2024--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced positive pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating taletrectinib, an investigational next-generation ROS1 TKI. The findings will be highlighted in a poster presentation on September 14, 2024, at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain
Evening Standard
Canelo vs Berlanga: UK fight time, ring walks, undercard, latest odds, prediction for boxing tonight
Another huge weekend of boxing in Las Vegas
The Independent
John Legend: ‘It was riskier for Taylor Swift to speak out about politics than it is for me’
THE SATURDAY INTERVIEW: The Egot-winning artist has turned his attention to children’s music for the first time with new album, ‘My Favorite Dream’. He chats politics, parenting and pregnancy journeys with Helen Coffey – and explains why social media trolling has lost its power over him and Chrissy Teigen
GlobeNewswire
NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024
Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses, and a Favorable Safety ProfileBARCELONA, Spain, Sept. 14, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy. In t
HuffPost Life
What To Do If You're No Longer Feeling Attracted To Your Partner
It's not unusual to feel less attracted to your partner over time. Here's why that happens — and what to do about it.
Evening Standard
Bianca Del Rio on life beyond the West End, bonding with Dame Judi Dench and eyeing Strictly Come Dancing
EXCLUSIVE: The US star reflected on a decade of success after winning Drag Race in 2014
Bloomberg
Europe’s Stock Leaders Are Fading in Bad Sign for Future Returns
(Bloomberg) -- The engines behind two years of European stock gains are losing power, leaving the region’s equities facing a void at a time when concerns over slowing growth and China tensions are testing investor confidence.Most Read from BloombergHousing’s Worst Crisis in Decades Reverberates Through 2024 RaceUS Driving and Congestion Rates Are Higher Than EverAn Affordable Nomadic Home Design Struggles to Adapt to Urban LifeFrom Louisville, a Push to Plant Trees for Public HealthThe Hague Is
GlobeNewswire
B2B Payments Market Size is Surpassing USD 4,151.35 Billion by 2033, Growing at Projected 9.38% CAGR
The global B2B payments market has grown due to rapid automation and digitization, greater international trade, and business sector expansion initiatives. Asia-Pacific emerged as the most significant global B2B payments market, with a 36.7% market revenue share in 2023.Newark, Sept. 14, 2024 (GLOBE NEWSWIRE) -- The global B2B payments market, valued at USD 1,693.60 billion in 2023, is expected to grow at a CAGR of 9.38% from 2024 to 2033. This growth is driven by the rapid adoption of automation
GlobeNewswire
Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors
This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain. 14 September 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Avacta Reports Updated Phase 1 Clinical Data of

NZX 50

NZD/USD

NZD/EUR

ALL ORDS

ASX 200

OIL

GOLD

NASDAQ

FTSE

Dow Jones

DAX

Hang Seng

NIKKEI 225

NZD/JPY

PLAYSTUDIOS to Release Third Quarter 2023 Results November 2

Latest stories

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Pope Francis launches scathing attack on Donald Trump and Kamala Harris in shock US election intervention

Funeral begins for Ugandan Olympian killed by ex-boyfriend

New dash cam trend on our roads that should spark fear in all of us

Biden scolds Sky News journalist for question on Putin’s Nato war threats

Strictly Come Dancing live: BBC show returns under a cloud of controversy as celebrity pairings to be revealed

RYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma

International Oscar Race: Nepal Selects ‘Shambhala’

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

No new pledge on Ukraine missiles after Starmer-Biden talks

Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024

Canelo vs Berlanga: UK fight time, ring walks, undercard, latest odds, prediction for boxing tonight

John Legend: ‘It was riskier for Taylor Swift to speak out about politics than it is for me’

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

What To Do If You're No Longer Feeling Attracted To Your Partner

Bianca Del Rio on life beyond the West End, bonding with Dame Judi Dench and eyeing Strictly Come Dancing

Europe’s Stock Leaders Are Fading in Bad Sign for Future Returns

B2B Payments Market Size is Surpassing USD 4,151.35 Billion by 2033, Growing at Projected 9.38% CAGR

Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors